Peer-reviewed veterinary case report
T cell lymphoma in 35 dogs treated with lomustine chemo
By Morgan, E et al.·Published in Veterinary and comparative oncology·2018·Department of Oncology, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs.
- Species:
- dog
Plain-English summary
A group of 35 dogs with T cell lymphoma (a type of cancer) were treated with a combination of chemotherapy drugs including lomustine, vincristine, procarbazine, and prednisolone. The treatment led to a median survival time of about 507 days, with many dogs showing significant improvement; 29 of them had a complete response to the therapy. While some dogs experienced mild side effects, the overall results suggest this chemotherapy protocol could be a promising option for treating T cell lymphoma in dogs.
People also search for: dog T cell lymphoma treatment · canine lymphoma chemotherapy · dog cancer survival rates
Abstract
Canine T cell lymphoma has previously been found to be a poor prognostic indicator compared with its B cell counterpart. The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma. There have been several studies investigating alternative protocols for T cell lymphoma. This study investigated the use of a modified lomustine, vincristine, procarbazine and prednisolone protocol as a first line treatment in 35 dogs with T Cell lymphoma. Median progression free survival (PFS) time for all 35 dogs was 431 days with a 6-month, 1-year, 2-year, and 3-year PFS of 69%, 54%, 29%, and 12%. Median survival time (MST) was 507 days. Twenty-nine dogs attained a complete response and had a median PFS time of 509 days. Thirty dogs experienced adverse events during the protocol, with 73% of these being grade 1 or 2. This protocol has shown increased median PFS time and MST compared with previous studies and suggests its use as a first line chemotherapy protocol against canine T cell lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30117253/